TAS-116
As of the edition of 20 October 2026, TAS-116 is a small molecule: marketed, first approved in 2022 (JP); acts on HSP90AA1 and HSP90AB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Jeselhy
- First approved
- 20 June 2022 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Taiho
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of TAS-116.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 2 | 1 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Taiho | Applicant and Lead sponsor of trials | 2017 to now |